Readers like you keep news free for everyone.

More than 5,000 readers have already pitched in to keep free access to The Journal.

For the price of one cup of coffee each week you can help keep paywalls away.

Support us today
Not now
Wednesday 4 October 2023 Dublin: 11°C
Hannah Marsh/John Birdsall/Press Association Images Model wear the breast cancer awareness pink ribbon
# Cancer
'Breakthrough' cancer test will not be offered to public patients
The National Centre for Pharmacoeconomics has said the test, which could help patients avoid chemotherapy, is too expensive to offer to public patients in Ireland.

A NEW TEST that could help women with cancer avoid having to undergo chemotherapy is not to be offered public patients because of costs.

The genetic test, called Oncotype DX, has been hailed as a breakthrough in breast cancer treatment as it can accurately identify the patients who remain at risk following surgery. The test, which could be of use to an estimated 400 to 500 women each year, can establish whether chemotherapy would be beneficial or not for a patient, reports the Sunday Business Post (see print edition).

The test has been available for years internationally but at a cost of about about €3,200 it is only available to private patients in Ireland, reports RTÉ.

The National Centre for Pharmacoeconomics has deemed the test too expensive for public patient use, but cancer doctors have pointed out that it could save money in the long-term as it would reduce the number of people seeking chemotherapy.

Your Voice
Readers Comments
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.